**S1 Table:**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  | **%IFNγ** | **%TNFα** | **%IL2** | **%IL17** | **%IL22** | **%any IFNγ,TNFα IL2** | **%anyIFNγ,IL2,IL17,IL22** |
| **DAR-901 treatment group** | **DAR-901 lysate stimulant** | **Baseline vs post-dose 3 D7** | 0.0078 \*\* | 0.0391 \* | 0.0078 \*\* | 0.0547  | 0.3828  | 0.0039 \*\* | 0.0039 \*\* |
| **Baseline vs post-dose 3 D180** | 0.0781  | 0.0977  | 0.1289  | 0.4258  | 0.2031  | 0.1641  | 0.0547  |
| **post-dose 3 D7 vs** **post-dose 3 D180** | 0.0078 \*\* | 0.3125  | 0.0547  | 0.1094  | 0.5469  | 0.0078 \*\* | 0.0156 \* |
| **MTB lysate stimulant** | **Baseline vs post-dose 3 D7** | 0.7344  | 0.8203  | 0.7344  | 0.5703  | 0.4258  | 0.5703  | 0.6250  |
| **Baseline vs post-dose 3 D180** | 0.8203  | 0.5703  | 0.1953  | 0.7344  | 0.7344  | 0.7344  | 0.9102  |
| **post-dose 3 D7 vs** **post-dose 3 D180** | 0.9453  | 0.9453  | 0.9453  | 0.2188  | 0.7109  | 0.1953  | 0.4609  |